Q3 2025 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2025-11-13 · accession 0001012975-25-000750
$59.6M
Reported value
24
Positions
2025-09-30
Period end
The Brief · Nan Fung Group Holdings Ltd · Q3 2025
AI · grounded in 13F
Nan Fung Group Holdings Ltd established a new position in OCS valued at $9.05M. The fund also initiated new stakes in MDGL for $5.45M and ONC for $5.36M. Additional new positions include INCY at $5.01M and RYTM at $4.96M. The fund ended the period with 24 positions and total AUM of $59.61M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| H5870P102 | OCS | OCULIS HOLDING AG | $9.0M | 15.2% | 514,702 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $5.4M | 9.13% | 11,872 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD | $5.4M | 8.99% | 15,722 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $5.0M | 8.40% | 59,022 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $5.0M | 8.32% | 49,120 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $4.7M | 7.95% | 300,000 | Common | SOLE |
| G65163100 | JOBY | JOBY AVIATION INC | $3.5M | 5.88% | 217,320 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $2.9M | 4.87% | 595,287 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $2.7M | 4.54% | 13,600 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $2.4M | 4.11% | 1,883,179 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $2.2M | 3.69% | 102,984 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $2.1M | 3.46% | 2,800 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $1.7M | 2.93% | 30,875 | Common | SOLE |
| 46438R105 | ETHA | ISHARES ETHEREUM TR | $1.6M | 2.67% | 50,549 | Common | SOLE |
| 773121108 | RKLB | ROCKET LAB CORP | $1.4M | 2.37% | 29,540 | Common | SOLE |
| 46438F101 | IBIT | ISHARES BITCOIN TRUST ETF | $1.0M | 1.74% | 15,968 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $899,115 | 1.51% | 19,253 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $745,470 | 1.25% | 27,049 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $533,619 | 0.90% | 68,943 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $310,406 | 0.52% | 58,347 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $284,676 | 0.48% | 49,082 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $266,983 | 0.45% | 63,719 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $246,693 | 0.41% | 493,584 | Common | SOLE |
| 09769B206 | BSLK | BOLT PROJS HLDGS INC | $153,457 | 0.26% | 40,597 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.